Coherus Oncology (NasdaqGM:CHRS) FY Conference Transcript

Coherus Oncology FY Conference Summary Company Overview - Company: Coherus Oncology (NasdaqGM:CHRS) - Date of Conference: March 04, 2026 - Focus: Transformation into an innovative oncology company, with significant debt reduction and product development initiatives Key Metrics and Financials - Debt Reduction: Reduced indebtedness by 90%, from approximately $480 million to $3.7 million in senior secured debt [2][6] - Cash Position: Strong balance sheet with $172 million at the end of Q4, further improved with recent financing [9] - Sales Growth: Sales of LOQTORZI increased from $19 million in 2024 to approximately $38 million in 2025, with expectations for continued growth in 2026 [5][10] Product Development and Pipeline LOQTORZI - Indication: Nasopharyngeal carcinoma (NPC) with a significant unmet need; launched in 2024 [7] - Market Opportunity: Estimated market size of $250 million, with a target of achieving $175 million in annual sales by 2028 [11] - Sales Strategy: Enhanced commercial team and sophisticated data acquisition tools to identify and reach patients [8][9] - Clinical Data: Demonstrated overall survival benefit of 65 months with LOQTORZI compared to 34 months with chemotherapy alone [4] Tagmokitug (Anti-CCR8 Antibody) - Mechanism: Targets T-regulatory cells (Tregs) selectively, showing 52%-97% depletion in tumors without affecting CD4s and CD8s [15][16] - Tumor Types: High potential across various solid tumors including head and neck, gastrointestinal, and breast cancers [17] - Clinical Development: Ongoing studies to optimize dosing and understand the best contexts for treatment [18][19] - Partnerships: Interest from larger companies for collaborations, particularly in combination therapies [23][24] Casdozokitug (Anti-IL-27) - Mechanism: Inhibits IL-27 to activate T cells and NK cells, showing promising results in liver and lung cancers [36][39] - Clinical Data: Achieved a 17% complete response rate in liver cancer, significantly higher than the previous highest of 8% [41] - Ongoing Studies: Randomized phase 2 study with initial readout expected mid-year 2026 [43] Strategic Insights - Transformation Strategy: Focus on product, clinical, and financial strategies to enhance investor value [52] - Market Positioning: Coherus aims to leverage its unique product offerings and partnerships to address significant gaps in oncology treatment [24][25] - Future Outlook: Anticipation of strong data readouts and continued growth in sales and clinical advancements [53] Additional Considerations - Collaborative Opportunities: Open to various licensing and partnership arrangements to reduce clinical trial costs and enhance development capabilities [25] - Biomarker Strategy: Potential to develop a biomarker strategy based on CCRA presence in tumors to enrich patient populations [32] This summary encapsulates the key points discussed during the Coherus Oncology FY Conference, highlighting the company's strategic direction, product pipeline, and financial health.